H.C. Wainwright lowered the firm’s price target on Lexicon (LXRX) to $4 from $6 and keeps a Buy rating on the shares. The company announced that following a “deficiencies preclude discussion” letter from the FDA related to Zynquista, it is implementing a strategic restructuring, eliminating its commercial operations, and rationalizing resources to preserve its cash position and prioritize its current clinical development pipeline, the analyst tells investors in a research note. The firm says Lexicon is eliminating commercial operations to concentrate on clinical progress.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LXRX:
- Lexicon to eliminate commercial organization, focus on clinical development
- Lexicon Pharmaceuticals Appoints Ivan Cheung to Board
- Lexicon announces data from four stories of sotagliflozin to be delivered
- Lexicon Pharmaceuticals Reports Q3 2024 Financial Results
- Lexicon reports Q3 EPS (18c), consensus (16c)